https://www.nasdaq.com/press-release/translational-data-at-sitc-2021-from-adaptimmunes-phase-1-surpass-trial-indicate
https://www.nasdaq.com/press-release/adaptimmune-reports-positive-results-from-its-pivotal-spearhead-1-trial-in-patients
https://www.nasdaq.com/press-release/adaptimmune-reports-third-quarter-financial-results-and-business-update-2021-11-04
https://www.nasdaq.com/press-release/adaptimmune-to-report-q3-2021-financial-results-and-business-update-on-thursday
https://www.nasdaq.com/press-release/adaptimmune-to-present-data-updates-at-upcoming-ctos-and-sitc-meetings-2021-10-05
https://www.nasdaq.com/press-release/adaptimmune-announces-clinical-responses-across-five-solid-tumor-indications-with-an
https://www.nasdaq.com/press-release/adaptimmune-enters-into-a-strategic-collaboration-with-genentech-to-research-develop
https://www.nasdaq.com/press-release/adaptimmune-updates-data-from-its-phase-1-trial-for-liver-cancer-at-ilca-showing
https://www.nasdaq.com/press-release/adaptimmune-reports-second-quarter-financial-results-and-business-update-2021-08-09
https://www.nasdaq.com/press-release/adaptimmune-to-report-q2-2021-financial-results-and-business-update-on-monday-august
https://www.nasdaq.com/press-release/two-complete-responses-and-response-rate-of-41-for-people-with-synovial-sarcoma
https://www.nasdaq.com/press-release/first-preclinical-data-from-adaptimmunes-mesothelin-hit-program-at-asgct-demonstrate
https://www.nasdaq.com/press-release/adaptimmune-reports-first-quarter-financial-results-and-business-update-2021-05-06
https://www.nasdaq.com/press-release/adaptimmune-to-present-first-preclinical-data-from-its-hla-independent-tcr-hit
https://www.nasdaq.com/press-release/adaptimmune-to-report-q1-2021-financial-results-and-business-update-on-thursday-may-6
https://www.nasdaq.com/press-release/adaptimmune-reports-fourth-quarter-full-year-2020-financial-results-and-business
https://www.nasdaq.com/press-release/adaptimmune-to-report-fourth-quarter-full-year-2020-financial-results-and-business
https://www.nasdaq.com/press-release/adaptimmune-to-showcase-market-potential-for-spear-t-cell-portfolio-and-pipeline-with
https://www.nasdaq.com/press-release/durable-responses-with-adp-a2m4-in-synovial-sarcoma-with-confirmed-responses-in-44-of
https://www.nasdaq.com/press-release/adaptimmune-to-host-virtual-investor-day-on-friday-november-20th-2020-11-12
https://www.nasdaq.com/press-release/two-confirmed-responses-and-five-out-of-six-patients-with-initial-tumor-reductions
https://www.nasdaq.com/press-release/adaptimmune-reports-q3-financial-results-and-business-update-2020-11-05
https://www.nasdaq.com/press-release/adaptimmune-to-report-q3-financial-results-and-business-update-on-thursday-november-5
https://www.nasdaq.com/press-release/adaptimmune-provides-full-contents-of-its-sitc-abstract-for-the-phase-1-surpass-trial
https://www.nasdaq.com/press-release/promising-data-from-phase-1-trial-with-adp-a2afp-in-liver-cancer-at-the-international
https://www.nasdaq.com/press-release/adaptimmune-reports-q2-financial-results-and-business-update-2020-08-06
https://www.nasdaq.com/press-release/adaptimmune-granted-access-to-priority-medicines-prime-regulatory-support-by-the
https://www.nasdaq.com/press-release/adaptimmune-to-report-q2-financial-results-and-business-update-on-thursday-august-6
https://www.nasdaq.com/press-release/adaptimmune-therapeutics-plc-announces-closing-of-public-offering-of-american-0
https://www.nasdaq.com/press-release/adaptimmune-therapeutics-plc-prices-public-offering-of-american-depositary-shares-0
https://www.nasdaq.com/press-release/adaptimmune-therapeutics-plc-proposes-public-offering-of-american-depositary-shares-0
https://www.nasdaq.com/press-release/spear-t-cells-targeting-mage-a4-demonstrate-new-responses-in-esophagogastric-junction
https://www.nasdaq.com/press-release/adaptimmune-reports-q1-financial-results-2020-05-14
https://www.nasdaq.com/press-release/spear-t-cells-derived-from-stem-cells-kill-cancer-targets-adaptimmune-presents
https://www.nasdaq.com/press-release/adaptimmune-to-report-q1-financial-results-on-thursday-may-14-2020-2020-04-29
https://www.nasdaq.com/press-release/positive-opinion-for-orphan-drug-designation-for-adp-a2m4-in-the-european-union-for
https://www.nasdaq.com/press-release/adaptimmune-reports-fourth-quarter-full-year-2019-financial-results-and-business
https://www.nasdaq.com/press-release/adaptimmune-to-report-full-year-q4-2019-financial-results-and-business-update-on
https://www.nasdaq.com/press-release/adaptimmune-announces-appointment-of-gavin-wood-as-chief-financial-officer-2020-02-18
https://www.nasdaq.com/press-release/adaptimmune-therapeutics-plc-announces-full-exercise-and-closing-of-underwriters
https://www.nasdaq.com/press-release/adaptimmune-therapeutics-plc-announces-closing-of-public-offering-of-american
https://www.nasdaq.com/press-release/adaptimmune-therapeutics-plc-prices-public-offering-of-american-depositary-shares
https://www.nasdaq.com/press-release/adaptimmune-therapeutics-plc-proposes-public-offering-of-american-depositary-shares
https://www.nasdaq.com/press-release/astellas-and-adaptimmune-enter-into-agreement-to-co-develop-and-co-commercialize-stem
https://www.nasdaq.com/press-release/adaptimmune-appoints-elliot-norry-as-chief-medical-officer-and-makes-changes-to-rd
https://www.nasdaq.com/press-release/adaptimmune-announces-that-spear-t-cell-platform-delivers-initial-responses-in-four
https://www.nasdaq.com/press-release/regenerative-medicine-advanced-therapy-designation-granted-by-fda-to-adp-a2m4-for-the
https://www.nasdaq.com/press-release/updated-data-from-phase-1-adp-a2m4-trial-demonstrating-continued-clinical-benefit-for
https://www.nasdaq.com/press-release/adaptimmune-reports-third-quarter-2019-financial-results-and-business-update-2019-11
https://www.nasdaq.com/press-release/adaptimmune-to-report-third-quarter-2019-financial-results-and-business-update-on
https://www.nasdaq.com/press-release/adaptimmune-and-cryoport-announce-agreement-to-ensure-safe-and-fully-monitored
https://www.nasdaq.com/press-release/adaptimmune-announces-appointment-of-michael-garone-as-interim-chief-financial
https://www.nasdaq.com/press-release/clear-benefit-for-patients-with-synovial-sarcoma-demonstrated-in-updated-data-from
https://www.nasdaq.com/press-release/united-states-orphan-drug-designation-for-treatment-of-soft-tissue-sarcomas-granted
https://www.nasdaq.com/press-release/adaptimmune-announces-oral-presentation-allogeneic-spear-t-cell-program-2019-asgct
https://www.nasdaq.com/press-release/adaptimmune-presents-safety-data-evidence-tumor-necrosis-one-patient-adp-a2afp-study
